Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $188

Author: Benzinga Newsdesk | March 20, 2024 07:58am
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $171 to $188.

Posted In: JAZZ

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist